A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment Naive Metastatic Anal Cancer Patients
Protocol: ECOG – EA2176 SCHEMA EA2176 Please Note: Below is partial eligibility, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 for full eligibility requirements. Thank you! Eligibility: Patient must have inoperable, recurrent, or metastatic disease (tumor resectability should be assessed by a local surgeon or a multidisciplinary team) not amenable […]